Acumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) will be issuing its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). During the same period in the prior year, the business earned ($0.28) EPS. On average, analysts expect Acumen Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Acumen Pharmaceuticals Price Performance

Shares of NASDAQ ABOS traded up $0.05 during mid-day trading on Wednesday, reaching $3.05. 22,662 shares of the company traded hands, compared to its average volume of 327,871. Acumen Pharmaceuticals has a fifty-two week low of $1.81 and a fifty-two week high of $5.09. The firm has a market cap of $183.24 million, a PE ratio of -2.68 and a beta of 0.04. The stock has a fifty day simple moving average of $2.56 and a 200-day simple moving average of $2.80. The company has a debt-to-equity ratio of 0.12, a current ratio of 17.37 and a quick ratio of 17.37.

Wall Street Analysts Forecast Growth

ABOS has been the topic of a number of research reports. UBS Group dropped their price objective on Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Citigroup raised Acumen Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Acumen Pharmaceuticals in a research note on Thursday, October 3rd.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.